Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of daprodustat vs darbepoetin alfa on forearm blood flow in non–dialysis-dependent CKD anemia
2017-002268-42Phase 2Terminated
- Sponsor
- GSK
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daprodustat in anaemia and chronic kidney disease (CKD) (2 arms), sponsored by GSK. Primary endpoint: Change in forearm blood flow (FBF) ratio in response to acetylcholine. Started Dec 2017; status: terminated.
02
Drugs
daprodustat
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2017-002268-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002268-42.